The FDA is freeing Intellia Therapeutics' CRISPR therapy from one of two clinical holds, allowing a phase 3 study to resume after a grade 4 liver event and subsequent patient death was reported in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results